ZYBERNO
Stock Report
Updated Aug 23, 2026

enVVeno Medical Corp (NVNO)

Healthcare • NASDAQ

$10.29

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
enVVeno Medical Corp (NVNO) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-62.3%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.12x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,083.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

enVVeno Medical Corp (NVNO) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, NVNO generated -$16.66M in Owner Earnings. Reinvestment rate: 1.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:10.29
Market Cap:$6.90M

Valuation Multiples (2)

P/B Ratio:0.33x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$14.09M

Price Action & Momentum (1)

% of 52-Week High:5.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-56.8%
Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-11.3%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$398.27
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-85.3%
Latest Earnings Filed:2026-07-30
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:11.70x
Quick Ratio:11.70x
Cash Ratio:11.39x

Leverage Analysis (3)

Debt To Equity Ttm:0.12x
Debt-to-Equity Ratio:0.12x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:20,195,000.00
Cash And Cash Equivalents:21,500,000.00
Long Term Debt:$103.00K
Net Debt:-$21.00M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$16.75M

Bottom Line Performance (3)

-$15.72M
Income Before Tax:-$19.47M
Ebitda Ttm:-16,627,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:8,720,000.00
Sga Expense:8,034,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$22.66M
Current Assets:$22.08M
Ppe Net:78,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:1,990,000.00
Current Liabilities:1,887,000.00
Long Term Debt:$103.00K
Short Term Debt:$402.00K

Equity & Capital (3)

Equity:$20.67M
Retained Earnings:-$178.78M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:540,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:467,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$14.79M-$16.66M

Investment Activities (1)

Investing Cash Flow:$2.77M

Financing Activities (3)

Financing Cash Flow:$782.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:782,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:127,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-43.77
-$43.77
Earnings Per Share Ttm:-$23.43

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$23.20

Book Value & Capital (2)

Book Value Per Share:$30.80
Cash Per Share:32.04

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$16.66M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-11.3%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-11.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:NVNO
Company Name:enVVeno Medical Corp
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:671.00K
Shares Outstanding Basic:671.00K
Shares Outstanding Diluted:671.00K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 05:55:37 UTC
Data Timestamp:2026-08-22T00:24:14.434394
Scroll to Top